https://orcid.org/0000-0002-5217-1034
References
- McKeigue PM, McAllister DA, Caldwell D, Gribben C, Bishop J, McGurnaghan S, et al. Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-scot case-control study. BMC Med 2021;19:149.
- Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination [Internet]. 2021 [cited 2021 Sep 15]. Available from: https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination
- Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724–36.
- Public Health Scotland. Search criteria for highest risk patients for shielding [Internet]. Public Health Scotland; 2021 [cited 2021 Dec 11]. Report No.: Version 6.0. Available from: https://hpspubsrepo.blob.core.windows.net/hps-website/nss/3008/documents/1_covid-19-search-criteria-highest-risk-patients.pdf
- Kanani N. Waller E. Caring for people at highest risk during COVID-19 incident [Internet]. Redditch, UK: NHS England; 2020. Available from: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/200321_GP-letter_Annex-2_FINAL_2.pdf
- McKeigue PM, Weir A, Bishop J, McGurnaghan SJ, Kennedy S, McAllister D, et al. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-Scot): a population-based case-control study. PLoS Med 2020;17:e1003374.
- National Institute for Health and Care Excellence. Equivalent anti-inflammatory doses: corticosteroids - oral [Internet]. NICE. 2020 [cited 2021 Sep 1]. Available from: https://cks.nice.org.uk/topics/corticosteroids-oral/background-information/equivalent-anti-inflammatory-doses/
- Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol 1978;108:299–307.
- Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J Epidemiol 1982;116:547–53.
- British Society for Rheumatology. COVID-19 - Identifying patients for shielding in England, Internet]. London, UK: British Society for Rheumatology; 2020. Report No.: V3. Available from: https://www.rheumatology.org.uk/Portals/0/Documents/COVID-19/Rheumatology_advice_coronavirus_immunosuppressed_patients_220320.pdf?ver=2020-03-24-171132-407
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 2020;584:430–6.
- Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius G-M, Baecklund E, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 2021;80:1086–93.
- Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859–66.
- Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021;80:1137–46.
- FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020;80:527–38.
- Kridin K, Schonmann Y, Damiani G, Peretz A, Onn E, Bitan DT, et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis – a population-based cohort study. Dermatol Ther 2021;34:e15003.
- Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S, et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity [Internet]. Rochester, NY: Social Science Research Network; 2021 [ cited 2021 Sep 1]. Report No.: ID 3910058. Available from: https://papers.ssrn.com/abstract=3910058